Cogent Biosciences, Inc. (COGT)
NASDAQ: COGT · Real-Time Price · USD
34.74
-0.05 (-0.14%)
May 8, 2026, 4:00 PM EDT - Market closed
Cogent Biosciences Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
258
Market Cap
5.94B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | 7.87M | -14.63M | -65.02% |
| Dec 31, 2019 | 22.50M | 12.77M | 131.14% |
| Dec 31, 2018 | 9.73M | 1.37M | 16.44% |
| Dec 31, 2017 | 8.36M | 2.01M | 31.55% |
| Dec 31, 2016 | 6.36M | 3.37M | 112.83% |
| Dec 31, 2015 | 2.99M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| PTC Therapeutics | 827.11M |
| Corcept Therapeutics | 769.10M |
| TG Therapeutics | 700.35M |
| Protagonist Therapeutics | 74.06M |
| Centessa Pharmaceuticals | 15.00M |
| CG Oncology | 5.07M |
COGT News
- 2 days ago - Cogent Biosciences price target raised to $55 from $52 at H.C. Wainwright - TheFly
- 4 days ago - Cogent Biosciences Reports Recent Business Highlights and First Quarter 2026 Financial Results - GlobeNewsWire
- 18 days ago - Cogent Biosciences Announces Oral Presentation of Positive Phase 3 PEAK Trial in Gastrointestinal Stromal Tumors (GIST) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting - GlobeNewsWire
- 22 days ago - Cogent Biosciences announces preclinical data from KRAS, ErbB2 programs - TheFly
- 22 days ago - Cogent Biosciences Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026 - GlobeNewsWire
- 5 weeks ago - Cogent Biosciences submits bezuclastinib new drug application to the FDA - TheFly
- 5 weeks ago - Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors (GIST) - GlobeNewsWire
- 7 weeks ago - Cogent Biosciences assumed with a Buy at Jefferies - TheFly